{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T10:33:37Z","timestamp":1702722817174},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.clml.2017.06.025","type":"journal-article","created":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T08:47:08Z","timestamp":1498294028000},"page":"696-702","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Analyses of Treatment Outcome According to Age in Patients With Chronic Myeloid Leukemia Receiving Front-line Imatinib Therapy"],"prefix":"10.1016","volume":"17","author":[{"given":"Irena","family":"\u0106ojba\u0161i\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lana","family":"Ma\u010dukanovi\u0107-Golubovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miodrag","family":"Vu\u010di\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Tijani\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.06.025_bib1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.beha.2009.07.007","article-title":"Epidemiology of chronic myeloid leukaemia (CML)","volume":"22","author":"Rohrbacher","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2017.06.025_bib2","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/leu.2008.245","article-title":"Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients: incidence and median age of Ph\/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany","volume":"23","author":"Rohrbacher","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.06.025_bib3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3322\/caac.20059","article-title":"Evaluating the older patient with cancer: understanding frailty and the geriatric assessment","volume":"60","author":"Pal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2017.06.025_bib4","first-page":"1233","article-title":"Old age is a sign of poor prognosis in patients with chronic myelogenous leukemia","volume":"80","author":"Kantarjian","year":"1988","journal-title":"Southern Med J"},{"key":"10.1016\/j.clml.2017.06.025_bib5","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0002-9343(97)89522-8","article-title":"Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older","volume":"100","author":"Cortes","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2017.06.025_bib6","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0145-2126(98)00064-2","article-title":"Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemia","volume":"22","author":"Hilbe","year":"1998","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2017.06.025_bib7","first-page":"513","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.06.025_bib8","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.06.025_bib9","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.025_bib10","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/cncr.11629","article-title":"Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome positive chronic myelogenous leukemia","volume":"98","author":"Cortes","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.06.025_bib11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3324\/haematol.10239","article-title":"Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party","volume":"92","author":"Rosti","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.06.025_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1179\/102453308X316004","article-title":"Use of imatinib mesylate in elderly patients in Northern Ireland: evidence of comparable haematological and molecular responses to younger patients","volume":"13","author":"Sheehy","year":"2008","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2017.06.025_bib13","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.amjmed.2010.03.018","article-title":"Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia","volume":"123","author":"Wiggins","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2017.06.025_bib14","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.leukres.2010.07.001","article-title":"\u201cReal life\u201d results of front-line treatment with imatinib in older patients (\u226565 years) with newly diagnosed chronic myelogenous leukemia","volume":"34","author":"Latagliata","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2017.06.025_bib15","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukaemia: recommendations from an expert panel on behalf of the European LeukaemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.025_bib16","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukaemia: an update of concepts and management: recommendations of the European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.025_bib17","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.025_bib18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.025_bib19","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A\u00a0new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa","volume":"90","author":"Hasford","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2017.06.025_bib20","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.025_bib21","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.06.025_bib22","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2015.152","article-title":"Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib","volume":"29","author":"Castagenetti","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.06.025_bib23","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries","volume":"29","author":"Hoffman","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.06.025_bib24","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.06.025_bib25","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","article-title":"Frontline imatinib treatment of chronic myeloid leukemia: no impact off age on outcome, a survey by the GIMEMA CML Working Party","volume":"117","author":"Gugliotta","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.025_bib26","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1182\/blood.V126.23.4038.4038","article-title":"Event-free survival according to age in patients with chronic myeloid leukemia receiving imatinib frontline: the younger, the later, the worse?","volume":"126","author":"Latagliata","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.025_bib27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/annonc\/mdu490","article-title":"Differences among young adults, adults and elderly chronic myeloid leukemia patients","volume":"26","author":"Castagnetti","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.06.025_bib28","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who\u00a0achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.025_bib29","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of non-adherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.025_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-017-0958-6","article-title":"Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors","volume":"34","author":"Rychter","year":"2017","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2017.06.025_bib31","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.leukres.2011.01.017","article-title":"Evaluation of tolerability and efficacy on imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study","volume":"35","author":"Sanchez-Gujio","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2017.06.025_bib32","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.leukres.2014.06.020","article-title":"Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival","volume":"38","author":"Breccia","year":"2014","journal-title":"Leuk Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017306900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017306900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T21:12:19Z","timestamp":1602364339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017306900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S2152265017306900"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.06.025","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analyses of Treatment Outcome According to Age in Patients With Chronic Myeloid Leukemia Receiving Front-line Imatinib Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.06.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}